PSMA PET for the Staging and Management of Hepatocellular Carcinoma
ConditionHepatocellular Carcinoma (HCC)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorVA Office of Research and Development
About this trial
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
Eligibility criteria
Qualifiers
Adult patients age >18 years from the VA medical system
Treatment-naïve patients with HCC with BCLC B or C disease
Disqualifiers
Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging
Patients with presence of active primary malignancy other than HCC and non-melanoma skin cancer in the past 3 years
Trial design
Treatments tested in this trial
- Not listed
Trial groups
90 Participants
are grouped into 3 trial groupsLocations
2VA Greater Los Angeles Healthcare System, West Los Angeles, CA90073-1003, West Los AngelesCalifornia, United States
Miami VA Healthcare System, Miami, FL33125, MiamiFlorida, United States
Sponsors and collaborators
VA Office of Research and Development
Lead sponsor
Miami VA Healthcare System
Collaborator
VA Medical Center-West Los Angeles
Collaborator
Source ClinicalTrials.gov